What is Q-Line Biotech revenue growth outlook?

Q-Line Biotech has a current market cap of ₹1,217 Cr and P/E ratio of 21.5. For detailed revenue growth insights derived from the latest earnings call, visit the Q-Line Biotech analysis page on Arthneeti AI.

What is Q-Line Biotech current stock price?

Q-Line Biotech current market price is ₹521.85. The stock trades at a P/E ratio of 21.5 with a market capitalisation of ₹1,217 Cr.

How does Arthneeti AI analyse Q-Line Biotech?

Arthneeti AI uses natural language processing to analyse Q-Line Biotech's earnings call transcripts and extract key insights on revenue growth, margins, capex plans, and fundraising activity. The analysis covers management commentary, forward guidance, and competitive positioning within the

Q-Line Biotech Q4 FY26 Share Price & Earnings Call Analysis

₹521.85+3.75% today

Market cap: ₹1,217 Cr
P/E: 21.50
ROE: 25.97%
PEG: 1.03
Price to sales: 3.56
Debt to equity: 0.92
EBITDA margin: 28.71%
Net profit margin: 16.57%
Promoter holding: 67.51%
Sales (last year): ₹342 Cr

All 10 ratios ↓

Guidance scorecard · Q4 FY26 call

What Q-Line Biotech's management guided

Revenue20–40%MarginsUp 2%+CapexPlanned FundraisingWhat management said Order bookRising

RevenueQ4 FY26 call

20–40%

Targeting revenue growth of approximately 30% to 35% in FY27 driven by increased utilization of manufacturing facilities and commercialization of new products.
Reagents revenue expected to grow by 30% to 35% in the current year, continuing as the primary growth driver due to recurring demand and strong margins.
Installed base of instruments growing with plans to add 2,000+ instruments in the current year, supporting recurring reagent sales.
Unit 4 manufacturing facility capacity expected to scale 3x to 4x current revenue in reagent and CDMO business by FY30.

2 more points from Q-Line Biotech's call on revenue

Create a free account to keep reading this call

Full Q4 FY26 analysis

MarginsQ4 FY26 call

Up 2%+

Q-Line Biotech targets revenue growth of approximately 30% to 35% for FY27, driven by increased utilization of manufacturing facilities, new product commercialization, export expansion, and disciplined cost management.
EBITDA margins are expected to remain steady or improve slightly, supported by higher sales of manufactured reagents with gross margins of 60-65%, and an expanding installed base driving recurring reagent revenues.
Receivable days are targeted to normalize within 90 to 120 days, improving working capital efficiency.
Profit after tax showed strong improvement in FY26 with PAT margin rising to 16.3%, and this trend is expected to continue due to operational leverage and improved product mix.

2 more points from Q-Line Biotech's call on margins

Create a free account to keep reading this call

See what Q-Line Biotech said on margins — free account, 30 seconds.

Full Q4 FY26 analysis

CapexQ4 FY26 call

Planned

No major capex expected in the next 2-3 years; current CWIP (~INR 15 crore) mostly for a new plant planned to be used as warehouse initially.
Additional capex possible if CDMO business for large equipment grows, requiring expanded space.
Unit 4 manufacturing capacity allows 3-4x current revenue growth without extra capex, supporting reagent and CDMO expansion.

2 more points from Q-Line Biotech's call on capex

Create a free account to keep reading this call

Full Q4 FY26 analysis

FundraisingQ4 FY26 call

Meenal Gupta (CFO) mentioned that the company likely has all the capex required for growth for the next 2-3 years and does not expect a large chunk of capex soon; existing CWIP might be used as warehouse temporarily.
Some past corporate guarantees extended to related parties are being wound up; IPO proceeds are being used to repay company debt.
The company expects corporate guarantees to be minimal going forward and does not plan to extend new guarantees.
Focus is on capital efficiency and profitable growth rather than raising fresh external capital.

See what Q-Line Biotech said on fundraising — free account, 30 seconds.

Full Q4 FY26 analysis

Order bookQ4 FY26 call

Rising

Q-Line Biotech has an installed base of approximately 16,000 to 17,000 diagnostic instruments to date.
The company plans to add around 2,000 new instruments in the current financial year.
Installed base increased by 2,500 instruments in the last two years.
Annual instrument placements average 1,200 to 1,300 units, with expected growth to over 2,000 units next year.

2 more points from Q-Line Biotech's call on the order book

Create a free account to keep reading this call

Full Q4 FY26 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

This quarter's potential multibaggers
on management's own guidance

See all potential multibaggers Where does Q-Line Biotech rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

1. Pick 3–15 stocks
2. Choose large, mid or small cap and your sectors
3. Get a portfolio built from the rankings

Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Financials of Q-Line Biotech

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Q-Line Biotech

Shareholding breakup across reporting periods.

	May 2026
Promoters +	67.51%
FIIs +	1.67%
DIIs +	10.14%
Public +	20.67%
No. of Shareholders	3,497

Pros & Cons

Q-Line Biotech

Key positives and risks surfaced from the company insights section.

Pros

Debtor days have increased from 92.7 to 134 days.

Raw Insights

Debtor days have increased from 92.7 to 134 days.

Financials of Q-Line Biotech

Quarterly Results

Quarter-by-quarter operating performance

No quarterly results data available for this company yet.

Financials of Q-Line Biotech

Profit & Loss

Annual income statement trend

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales +	183	203	313	342
Expenses +	149	165	242	244
Operating Profit	34	38	71	98
OPM %	18%	19%	23%	29%
Other Income +	2	3	-14	5
Interest	4	6	15	19
Depreciation	2	4	7	11
Profit before tax	30	31	35	73
Tax %	28%	29%	55%	23%
Net Profit +	32	34	19	56
EPS in Rs	203.81	218.67	121.97	34.24
Dividend Payout %	0%	0%	0%	0%

Financials of Q-Line Biotech

Balance Sheet

Capital structure and asset base

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2	2	2	16
Reserves	126	160	188	230
Borrowings +	74	97	166	225
Other Liabilities +	51	81	99	87
Total Liabilities	252	339	455	559
Fixed Assets +	23	60	91	158
CWIP	12	19	63	19
Investments	16	29	0	0
Other Assets +	201	232	302	381
Total Assets	252	339	455	559

Financials of Q-Line Biotech

Cash Flows

Operating, investing and financing cash movement

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	25	-24	17	16
Cash from Investing Activity +	-26	-45	-77	-29
Cash from Financing Activity +	26	17	53	42
Net Cash Flow	25	-52	-7	29
Free Cash Flow	-5	-72	-53	-19
CFO/OP	111%	-39%	36%	43%

Financials of Q-Line Biotech

Ratios

Working capital efficiency and return ratios

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	66	47	96	134
Inventory Days	180	413	225	258
Days Payable	164	232	139	142
Cash Conversion Cycle	82	228	183	251
Working Capital Days	-44	51	45	62
ROCE %		16%	24%	22%

What Q-Line Biotech's management said in earlier quarters

Q4 FY26 earnings call analysis →

Q-Line Biotech Q4 FY26 Share Price & Earnings Call Analysis

What Q-Line Biotech's management guided

RevenueQ4 FY26 call

MarginsQ4 FY26 call

CapexQ4 FY26 call

FundraisingQ4 FY26 call

Order bookQ4 FY26 call

This quarter's potential multibaggers on management's own guidance

Build your portfolio from the top-ranked stocks

Financials of Q-Line Biotech

Q-Line Biotech

Q-Line Biotech

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Continue your research

What Q-Line Biotech's management said in earlier quarters

This quarter's potential multibaggers
on management's own guidance

Build your portfolio
from the top-ranked stocks